Aerovate Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · | ||||||||||||||||||
| · · · · · · · · Accumulated · · · · · | ||||||||||||||||||
| · · · · · Additional · Other · · · · Total · | ||||||||||||||||||
| · Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ · | ||||||||||||||||||
| · Shares · Amount · Capital · Gain/(Loss) · Deficit · Equity · | ||||||||||||||||||
| Balance at December 31, 2023 | 27,762,703 | | $3 | | $272,640 | | $237 | | $(163,424) | | $109,456 | | ||||||
| Unrealized loss on investments | — | | — | | — | | (270) | | — | | (270) | | ||||||
| Issuance of common stock upon exercise of stock options | | 133,282 | | | — | | | 704 | | | — | | | — | | | 704 | |
| Vesting of restricted stock units | | 2,776 | | | — | | | — | | | — | | | — | | | — | |
| Stock based compensation | — | | — | | 4,200 | | — | | — | | 4,200 | | ||||||
| Net loss | — | | — | | — | | — | | (23,186) | | (23,186) | | ||||||
| Balance at March 31, 2024 | 27,898,761 | | $3 | | $277,544 | | $(33) | | $(186,610) | | $90,904 | | ||||||
| Unrealized loss on investments | — | | | — | | | — | | | (50) | | | — | | (50) | | ||
| Issuance of common stock in connection with ATM, net | | 800,000 | | | — | | | 23,635 | | | — | | | — | | | 23,635 | |
| Issuance of common stock upon exercise of stock options | 119,239 | | | — | | | 511 | | | — | | | — | | 511 | | ||
| Issuance of common stock under ESPP | | 34,034 | | | — | | | 308 | | | — | | | — | | | 308 | |
| Vesting of restricted stock units | | 2,716 | | | — | | | — | | | — | | | — | | | — | |
| Stock based compensation | | — | | | — | | | 3,865 | | | — | | | — | | | 3,865 | |
| Net loss | — | | | — | | | — | | | — | | | (24,775) | | (24,775) | | ||
| Balance at June 30, 2024 | 28,854,750 | | $3 | | $305,863 | | $(83) | | $(211,385) | | $94,398 | | ||||||
| Unrealized gain on investments | | — | | | — | | | — | | | 307 | | | — | | | 307 | |
| Issuance of common stock upon exercise of stock options | | 12,961 | | | — | | | 22 | | | — | | | — | | | 22 | |
| Stock based compensation | | — | | | — | | | 2,003 | | | — | | | — | | | 2,003 | |
| Net loss | | — | | | — | | | — | | | — | | | (16,237) | | | (16,237) | |
| Balance at September 30, 2024 | | 28,867,711 | | $3 | | $307,888 | | $224 | | $(227,622) | | $80,493 | | |||||
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · · | ||||||||||||||||||
| · · · · · · · · · Accumulated · · · · | ||||||||||||||||||
| · · · · · Additional · · Other · · Total · | ||||||||||||||||||
| · Common Stock · Paid-In · · Comprehensive · Accumulated · Stockholders’ · | ||||||||||||||||||
| · Shares · Amount · Capital · Gain/(Loss) · Deficit · Equity · | ||||||||||||||||||
| Balance at December 31, 2022 | | 24,722,974 | | $2 | | $215,110 | | $(466) | | $(87,903) | | $126,743 | | |||||
| Unrealized gain on investments | — | | — | | — | | 265 | | — | | 265 | | ||||||
| Issuance of common stock upon exercise of stock options | | 93,966 | | | — | | | 223 | | | — | | | — | | | 223 | |
| Stock based compensation | — | | — | | 2,384 | | — | | — | | 2,384 | | ||||||
| Net loss | — | | — | | — | | — | | (16,520) | | (16,520) | | ||||||
| Balance at March 31, 2023 | 24,816,940 | | $2 | | $217,717 | | $(201) | | $(104,423) | | $113,095 | | ||||||
| Unrealized loss on investments | | — | | | — | | | — | | | (22) | | | — | | | (22) | |
| Issuance of common stock in connection with ATM, net | | 2,662,721 | | | 1 | | | 44,282 | | | — | | | — | | | 44,283 | |
| Issuance of common stock upon exercise of stock options | | 106,756 | | | — | | | 333 | | | — | | | — | | | 333 | |
| Issuance of common stock under ESPP | | 13,866 | | | — | | | 228 | | | — | | | — | | | 228 | |
| Vesting of restricted stock units | | 815 | | | — | | | | | | — | | | — | | | — | |
| Stock based compensation | — | | — | | 3,034 | | — | | — | | 3,034 | | ||||||
| Net loss | — | | — | | — | | — | | (19,025) | | (19,025) | | ||||||
| Balance at June 30, 2023 | 27,601,098 | | $3 | | $265,594 | | $(223) | | $(123,448) | | $141,926 | | ||||||
| Unrealized gain on investments | — | | — | | — | | 28 | | — | | 28 | | ||||||
| Issuance of common stock upon exercise of stock options | | 46,777 | | | — | | | 95 | | | — | | | — | | | 95 | |
| Vesting of restricted stock units | | 5,312 | | | — | | | — | | | — | | | — | | | — | |
| Stock based compensation | — | | — | | 3,237 | | — | | — | | 3,237 | | ||||||
| Net loss | — | | — | | — | | — | | (19,563) | | (19,563) | | ||||||
| Balance at September 30, 2023 | 27,653,187 | | $3 | | $268,926 | | $(195) | | $(143,011) | | $125,723 | | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.